Novel Anti-Amyloidal Alzheimer's Drug Candidate Caprospinol
.
Alzheimer's Donation
Donate Online Now
.
Samaritan Pharmaceuticals Inc. and Samaritan Pharma Ireland, Inc. (AMEX:LIV) developers of innovative drugs, announced today it has submitted an Investigational New Drug (IND) application to evaluate its lead compound Caprospinol (SP-233) as a potentially new and novel pharmaceutical treatment for Alzheimer's disease. This is an important first step, to test Caprospinol's future in humans, as a potential memory-saving Alzheimer's drug.


Unlike drugs currently used to treat Alzheimer's that just alleviate symptoms, Caprospinol might potentially be a viable treatment for the disease itself. Preclinical studies have shown that Caprospinol targets and binds to the beta-amyloid protein, washing out beta-amyloid plaque from the brain. Today, the beta-amyloid protein is what most researchers believe is the cause of Alzheimer's disease.

Scientists at Samaritan Laboratories, Georgetown University, led the preclinical studies for Caprospinol, while Samaritan's Drug Development executives amassed the seven thousand pages of data to formulate the IND submitted to the FDA. PharmaPlaz, Ireland, Samaritan's collaborative manufacturing partner, led the chemistry, manufacturing and controls (CMC) section of the submitted IND.

Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "The long race to develop a cure, or even a viable treatment, for Alzheimer's disease is quickly turning into a sprint for Samaritan. We at Samaritan are extremely excited to apply to enter the sprint and will do everything possible to remain in the running to find a cure or viable treatment for this horrible disease."